RLAY compared with AMLX: revenue, margins and what each company keeps, and the suppliers and customers both name

RLAYRelay Therapeutics, Inc.

Mkt capRevenueRevenue

AMLXAmylyx Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

RLAYRelay Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RLAY

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±17.0%▲+0.10%×0.01

May 6 '26±14.2%▼−0.62%×0.04

Q1 FY26±40.7%▲+12.01%×0.29

Q3 FY25±32.5%▼−7.35%×0.22

AMLX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.6%▲+10.71%×0.42

May 7 '26±11.9%▼−5.35%×0.45

= impliedRLAY realized, solidAMLX realized, hatchedOne scale, both sides: full bar = 41%× = |realized| ÷ impliedSource: market data

Q1 FY26

±17.6%

▼−7.78%

×0.44

Nov 6 '25±18.9%▼−5.89%×0.31

RLAYRelay Therapeutics, Inc.

17.49▼−4.71%

Mkt cap$4.0BRevenue$350,000Q2 FY26

AMLXAmylyx Pharmaceuticals, Inc.

27.92▼−3.27%

Regular sessionNov 2 '26

Mkt cap$3.2BRevenue$416,000Q3 FY24

Compare

Regular sessionNov 2 '26

RLAYRelay Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals, Inc.

17.49▼−4.71%

Price

27.92▼−3.27%

$4.0B

Mkt cap

$3.2B

Q2 FY26$350,000

Revenue

$416,000Q3 FY24

RLAY17.49▼−4.71%vsAMLX27.92▼−3.27%Regular sessionNov 2 '26